Infliximab is a chimeric monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine central to neuroinflammation in Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. It is FDA-approved for autoimmune diseases including rheumatoid arthritis, Crohn's disease, ulcerative colitis, and ankylosing spondylitis, and is being investigated for neuroprotection in degenerative brain diseases.
Mechanism of Action
TNF-alpha in Neurodegeneration
TNF-alpha is a key mediator of chronic neuroinflammation:
Pro-inflammatory Signaling: TNF-α activates [NF-κB](/mechanisms/nf-kb-pathway) and MAPK pathways in [microglia](/entities/microglia) and [astrocytes](/cell-types/astrocytes), leading to production of more cytokines and chemokines. This creates a self-perpetuating inflammatory loop that drives progressive neuronal dysfunction.
Excitotoxicity: TNF-α enhances glutamate-induced neuronal toxicity by increasing AMPA receptor trafficking to the synaptic membrane, leading to calcium dysregulation and excitotoxic cell death.
[Blood-Brain Barrier](/mechanisms/blood-brain-barrier) Disruption: TNF-α increases [BBB](/entities/blood-brain-barrier) permeability by downregulating tight junction proteins (claudin-5, occludin), allowing peripheral immune cells to enter the CNS and exacerbate inflammation.
Synaptic Pruning: Elevated TNF-α promotes excessive synaptic elimination by [microglia](/cell-types/microglia-neuroinflammation) through complement-mediated pathways, contributing to synaptic loss in AD and PD.
Mitochondrial Dysfunction: TNF-α signaling impairs mitochondrial function by inhibiting complex I and increasing [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production.
Infliximab Mechanism
Infliximab is a chimeric IgG1 monoclonal antibody that:
Binds to both soluble and membrane-bound TNF-α with high affinity (KD ~ 10^-11 M)
Prevents TNF-α from binding to its receptors (TNFR1/p55, TNFR2/p75)
May induce [apoptosis](/entities/apoptosis) of TNF-α-expressing cells through antibody-dependent cellular cytotoxicity
Does not bind to other TNF family members (lymphotoxin-α, TRAIL)
Clinical Evidence
Alzheimer's Disease (NCT02878616)
Phase II trial sponsored by University of California, Los Angeles
Objective: Evaluate infliximab safety and CSF biomarkers in mild cognitive impairment and AD
Status: Completed (results published 2023)
Key findings: Treatment was safe; trend toward reduction in CSF inflammatory markers
Parkinson's Disease
Preclinical evidence: TNF-α levels are elevated in PD brains (substantia nigra) and CSF
Case reports: Patients with comorbid autoimmune disease showed PD symptom improvement on TNF inhibitors
Observational studies: Reduced PD incidence in patients on chronic TNF therapy for autoimmune conditions
No large Phase II/III trials completed as of 2026
Amyotrophic Lateral Sclerosis (ALS)
Rationale: Neuroinflammation is a key contributor to ALS progression
Evidence: Elevated TNF-α in ALS patient CSF and spinal cord
Clinical trials: No completed trials as of 2026
Multiple Sclerosis
Paradoxical finding: TNF inhibitors can trigger demyelinating disease
Lesson: Timing and patient selection are critical for anti-TNF therapy in CNS diseases
Dosage and Administration
In autoimmune diseases:
Induction: 3-5 mg/kg IV at weeks 0, 2, 6
Maintenance: Every 8 weeks thereafter
For neurodegeneration trials, similar dosing has been used:
5 mg/kg IV infusion over 2 hours
Pre-medication with antihistamine and acetaminophen recommended
Monitoring required for infusion reactions
Side Effects
Common (>10%):
Infusion reactions (headache, flushing, dyspnea)
Headache
Upper respiratory infections
Nausea
Serious:
Serious infections (reactivation of TB, bacterial, fungal)
Heart failure exacerbation
Demyelinating disease
Liver injury (elevated transaminases)
Increased risk of certain malignancies (lymphoma, non-melanoma skin cancer)
Psoriasis or psoriasiform eruptions
Comparison with Other Anti-cytokine Therapies
Research Directions
Biomarker-Driven Patient Selection
Select patients with elevated peripheral inflammatory markers (CRP, IL-6)
Use CSF TNF-α or sTREM2 levels as enrichment biomarkers
Target patients with evidence of systemic inflammation
Combination Approaches
Combine with disease-modifying therapies targeting protein aggregation
Pair with anti-amyloid or anti-[tau](/proteins/tau) immunotherapies
Use with antioxidants or mitochondrial protectants
Timing of Intervention
Earlier intervention in prodromal or mild cognitive impairment stages
Consider preventive therapy in high-risk populations
Avoid in patients with established advanced neurodegeneration
Novel Delivery Methods
Investigate intrathecal or convection-enhanced delivery for higher CNS penetration
Develop TNF-neutralizing fragments with better brain access
The study of Infliximab For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions